名臣健康(002919) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥171,609,104.93, a decrease of 16.34% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥22,121,912.27, down 28.41% year-on-year, while the net profit excluding non-recurring gains and losses was ¥21,275,078.22, a decrease of 33.64%[3]. - Total operating revenue for Q3 2021 reached ¥572,884,248.33, an increase from ¥444,395,559.52 in the previous period[23]. - Operating profit for the period was ¥120,971,502.78, compared to ¥54,312,182.04 in the same period last year, reflecting a significant growth[24]. - Net profit for Q3 2021 was ¥121,021,881.50, up from ¥46,897,099.26 in the previous year, indicating a year-over-year increase of approximately 158%[24]. - Total comprehensive income for the period reached CNY 121,021,881.50, compared to CNY 46,897,099.26 in the previous period, indicating a significant increase[25]. - Basic and diluted earnings per share were both CNY 0.99, up from CNY 0.38 in the same period last year, reflecting strong profitability growth[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥909,953,766.03, reflecting a 3.50% increase from the end of the previous year[3]. - Total assets amounted to ¥909,953,766.03, an increase from ¥879,177,170.27 at the end of the previous period[22]. - Total liabilities decreased to ¥164,584,464.47 from ¥223,715,822.15, indicating improved financial stability[21]. - Current liabilities reached ¥220.92 million, with accounts payable at ¥70.17 million and short-term borrowings at ¥39.05 million[31]. - Total liabilities were reported at ¥223.72 million, with non-current liabilities accounting for ¥2.80 million[32]. - Owner's equity totaled ¥655.46 million, with retained earnings of ¥190.83 million and capital reserves of ¥323.23 million[32]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥3,494,620.54, a decline of 104.56% compared to the same period last year[9]. - Cash inflows from operating activities totaled CNY 603,783,936.54, compared to CNY 504,359,298.12 in the previous period, representing an increase of approximately 19.7%[26]. - The net cash flow from operating activities was negative at CNY -3,494,620.54, a decline from CNY 76,662,629.14 in the prior year, indicating operational challenges[28]. - Cash inflows from investment activities amounted to CNY 374,835,397.52, compared to CNY 346,226,953.20 in the previous period, showing a growth of about 8.3%[28]. - The net cash flow from investment activities was CNY 54,273,560.50, a significant improvement from CNY -364,957,564.85 in the same period last year[28]. - Cash and cash equivalents at the end of the period were CNY 175,823,317.82, down from CNY 198,712,001.88 at the beginning of the period[28]. - Total cash outflows from operating activities were CNY 607,278,557.08, compared to CNY 427,696,668.98 in the previous period, indicating increased operational expenses[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 4,421[12]. - The largest shareholder, Chen Qinfang, holds 37.00% of the shares, amounting to 45,193,500 shares[12]. - Liu Xiaowei, the second-largest shareholder, holds 12.33% of the shares, totaling 15,064,500 shares[12]. Research and Development - The company reported a significant increase in research and development expenses, which rose by 256.54% to ¥69,316,626.75 due to new subsidiary investments[8]. - Research and development expenses surged to ¥69,316,626.75, compared to ¥19,441,357.35 in the prior period, highlighting a focus on innovation[23]. Corporate Governance - The company is in the process of electing new board members, with nominations for both non-independent and independent directors[13]. - The third board of supervisors will include representatives elected from the employee representative assembly[14]. - The company has completed the registration change for its legal representative following the election of the new board chairman[17]. - The company is actively engaging in corporate governance changes, including the appointment of senior management[16]. - The company has disclosed its governance changes through various financial news platforms[15]. Other Financial Metrics - The company has a cash balance of 175,823,317.82 yuan as of September 30, 2021, down from 198,712,001.88 yuan at the end of 2020[19]. - Trading financial assets decreased from 114,874,489.58 yuan at the end of 2020 to 50,376,157.05 yuan by September 30, 2021[19]. - The company has adopted new leasing standards starting from 2021, which may impact future financial reporting and asset valuations[29]. - The report indicates a significant increase in intangible assets, totaling ¥14.89 million[31]. - Deferred tax assets were recorded at ¥9.39 million, contributing to the overall asset structure[31]. - The company has a lease liability of ¥12.17 million, reflecting its commitments under new leasing standards[32]. - The report highlights a total of ¥47.38 million in contract liabilities, indicating future revenue obligations[31]. - The company has not disclosed any new product developments or market expansion strategies in this report[33].